1. Home
  2. YDKG vs VIVS Comparison

YDKG vs VIVS Comparison

Compare YDKG & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yueda Digital Holding Class A Ordinary Share

YDKG

Yueda Digital Holding Class A Ordinary Share

N/A

Current Price

$0.89

Market Cap

4.6M

ML Signal

N/A

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.71

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDKG
VIVS
Founded
2005
2007
Country
China
United States
Employees
17
9
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YDKG
VIVS
Price
$0.89
$1.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
66.5K
67.9K
Earning Date
05-01-2026
06-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$1.42
52 Week High
$3.90
$5.30

Technical Indicators

Market Signals
Indicator
YDKG
VIVS
Relative Strength Index (RSI) 51.96 40.17
Support Level $0.81 N/A
Resistance Level $0.94 $2.08
Average True Range (ATR) 0.04 0.09
MACD 0.01 -0.01
Stochastic Oscillator 76.70 31.68

Price Performance

Historical Comparison
YDKG
VIVS

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: